


KILL THE UGLY BUG?






TAKE HOME MESSAGE H. PYLORI ERADICATION 2020

Permanent cure for PEPTIC ULCER DISEASE

Use in CANCER PREVENTION is controversial

WHO – Class I carcinogen

AmJGastroenterol 2019;114:1827-183



¿CANCERIGENO? UN POQUITO PARA ATRAS POR FAVOR

Veamos la historia

200,000 BC - 2020

Spreading Throughout the Globe Arctic Ocean 15,000 Modern humans did not The desolate tundras of appear in Europe until 40,000 Siberia were first occupied to 35,000 years ago. These by humans as late as The timing of the first first Europeans are usually 25,000 years ago. 25,000 called the Cro-Magnon. crossing of Beringia is still a hotly debated issue. No clear evidence has yet been found to indicate that humans migrated to North America earlier than 15,000 years ago. 100,000 Pacific 70,000 The earliest dating for modern humans so far obtained in East Ocean Asia—67,000 years ago—is from Liujiang, in southern China. Findings from the caves of Mount Carmel indicate that modern humans appeared outside Africa Atlantic for the first time about 100,000 years ago. Ocean Indian Ocean 50,000 200,000 Human occupation of Australia The probable area of origin of dates back at least 50,000 years. our own species is southeastern It may have occurred even earlier, Africa. Anatomically modern humans but the evidence of this first evolved there at least 200,000 years ago. settlement today lies below sea level.




J.R. WARREN & B. MARSHAL

- Lancet 1983 1:273-5
- 2005 Nobel Price


"Opportunity only favors the trained mind"

- Louis Pasteur


H. PYLORI SURVIVAL ADAPTATION — MOTILITY



SURVIVAL ADAPTATION — UREASE



NATURAL HISTORY





- Active PUD (gastric or duodenal)
- Confirmed history of PUD not previously treated for H. pylori
- Gastric MALT lymphoma (low grade)
- After endoscopic resection of Early Gastric Cancer
- Patients taking low-dose aspirin or starting therapy with NSAID
- Unexplained iron deficiency anemia
- Idiopathic thrombocytopenic purpura

TREATMENT OF H. PYLORI INFECTION

PRIMARY CARE

- Active PUD (gastric or duodenal)
- Confirmed history of PUD not previously treated for H. pylor
- Patients taking low-dose aspirin or starting therapy with NSAID

SPECIALTY CARE

- Gastric MALT lymphoma (low grade)
- After endoscopic resection of Gastric
 Ca
- Unexplained iron deficiency anemia,
- ITP Idiopathic Thrombocytopenic Purpura



TREATMENT EVALUATION

The Best Test Nobody Uses

Stool Antigen Test

STOOL ANTIGEN TEST FOR H. PYLORI


- Affected by PPI & antibiotic use Discontinue
- Useful before and after treatment
- A positive test confirms active infection
 - > The bug is ALIVE
- A negative test post treatment confirms eradication
 - > The bug is DEAD



THE PROBLEM 2020

Antibiotic Resistance Is Affecting H. pylori Treatment

Clarithromycin containing standard triple therapies are no longer suitable for unconditional empirical use.



¿QDÉ HAGO?


"Amigo del Chase"

NEW TREATMENT GRAHAM DY ET AL. ANN INTERN MED MAY 2020

- Rifabutin-based regimen recently approved by the FDA for H. pylori treatment in adults
- Randomized treatment with capsules containing rifabutin, amoxicillin and omeprazole or capsules containing amoxicillin and omeprazole for 14 days

RESULTS

- Therapy group eradication rate 84%
- Comparison group eradication rate 58%
- In patients with confirmed adherence to treatment, the eradication rates were 90% versus 65%, respectively
- No H. pylori resistance to rifabutin was detected and side effects were similar between groups



OLDIES BUT GOODIES BISMUTH QUADRUPLE

- PPI STANDARD DOSE
- BISMUTH 300mg TAB QID
- TETRACYCLINE 500mg QID
- METRONIDAZOLE 250mg TID / QID



CANCER MASS SCREENING CRITERIA

- Major health problem
- Available effective therapy
- Available sensitive test
- Acceptable to patients
- Cost effective



¿PORQUE NO LOS VACUNAMOS?

Molto difficile

SUSCEPTIBILITY PATTERN AND GENOTYPIC CHARACTERIZATION OF H. PYLORI ISOLATES FROM PR

105th American Society for Microbiology, Atlanta, Georgia

June 5-8, 2005

Lebrón RF, Vázquez GJ, Robledo IE.